Literature DB >> 22852028

Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem.

Mai Ahmed Banakhar1, Tariq Al-Shaiji, Magdy Hassouna.   

Abstract

Overactive bladder (OAB) syndrome negatively affects the daily life of many people. Conservative treatments, such as antimuscarinics, do not always lead to sufficient improvement of the complaints and are often associated with considerable side effects resulting in treatment failure. In the case of failure or intolerable side effects, sacral neuromodulation (SNM) and botulinum toxin intravesical injections are minimally invasive and reversible alternatives. Currently, both SNM and botulinum toxin injection have FDA approval for use in OAB patients. This mini-review attempts to provide an update on SNM as a second-line management of adults with refractory OAB, based on the available clinical evidence concerning the efficacy and safety.

Entities:  

Keywords:  overactive bladder; sacral neuromodulation

Year:  2012        PMID: 22852028      PMCID: PMC3398598          DOI: 10.1177/1756287212445179

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  34 in total

1.  Urodynamic results of sacral neuromodulation correlate with subjective improvement in patients with an overactive bladder.

Authors:  W A Scheepens; G A van Koeveringe; R A de Bie; E H J Weil; Ph E V van Kerrebroeck
Journal:  Eur Urol       Date:  2003-03       Impact factor: 20.096

2.  Bladder and urethral sphincter responses evoked by microstimulation of S2 sacral spinal cord in spinal cord intact and chronic spinal cord injured cats.

Authors:  Changfeng Tai; August M Booth; William C de Groat; James R Roppolo
Journal:  Exp Neurol       Date:  2004-11       Impact factor: 5.330

3.  Prevalence of the overactive bladder syndrome by applying the International Continence Society definition.

Authors:  Christian Temml; Stefan Heidler; Anton Ponholzer; Stephan Madersbacher
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

4.  Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study.

Authors:  A C van Voskuilen; D J A J Oerlemans; E H J Weil; R A de Bie; Ph E V A van Kerrebroeck
Journal:  Eur Urol       Date:  2006-01-04       Impact factor: 20.096

5.  Electric pelvic floor stimulation. Mechanism of action.

Authors:  C T Teague; D C Merrill
Journal:  Invest Urol       Date:  1977-07

6.  Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method?

Authors:  Thomas M Kessler; Helmut Madersbacher; Gustav Kiss
Journal:  Eur Urol       Date:  2005-01-04       Impact factor: 20.096

7.  Failure of sacral nerve stimulation due to migration of tined lead.

Authors:  Donna Y Deng; Mittul Gulati; Matthew Rutman; Shlomo Raz; Larissa V Rodríguez
Journal:  J Urol       Date:  2006-06       Impact factor: 7.450

8.  A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation.

Authors:  K Everaert; W Kerckhaert; H Caluwaerts; M Audenaert; H Vereecke; G De Cuypere; A Boelaert; U Van den Hombergh; W Oosterlinck
Journal:  Eur Urol       Date:  2004-05       Impact factor: 20.096

9.  The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey.

Authors:  Karin S Coyne; Chris Payne; Samir K Bhattacharyya; Dennis A Revicki; Christine Thompson; Ron Corey; Timothy L Hunt
Journal:  Value Health       Date:  2004 Jul-Aug       Impact factor: 5.725

10.  Sacral neuromodulation for the treatment of refractory interstitial cystitis: outcomes based on technique.

Authors:  Kenneth M Peters; Jeffrey M Carey; David B Konstandt
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-08-26
View more
  4 in total

1.  Percutaneous Nerve Evaluation Test Versus Staged Test Trials for Sacral Neuromodulation: Sensitivity, Specificity, and Predictive Values of Each Technique.

Authors:  Mai Banakhar; Magdy Hassouna
Journal:  Int Neurourol J       Date:  2016-09-23       Impact factor: 2.835

2.  Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.

Authors:  Chi-Wen Lo; Mei-Yi Wu; Stephen Shei-Dei Yang; Fu-Shan Jaw; Shang-Jen Chang
Journal:  Toxins (Basel)       Date:  2020-02-18       Impact factor: 4.546

3.  Sacral neuromodulation for neurological disease-induced lower urinary tract symptoms in Saudi Arabia: a single-centre experience.

Authors:  Mai Ahmed Banakhar
Journal:  J Int Med Res       Date:  2022-08       Impact factor: 1.573

4.  Effect of sacral neuromodulation on female sexual function and quality of life: Are they correlated?

Authors:  Mai Banakhar; Yahya Gazwani; Mohamed El Kelini; Tariq Al-Shaiji; Magdy Hassouna
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.